Related Experiment Video
Updated: Apr 16, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Viral gene therapy for head and neck cancer
J P Hughes1, G Alusi1, Y Wang1
1Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London,UK.
Background:
Viral gene therapy is a promising new treatment modality for head and neck cancer. This paper provides the reader with a review of the relevant literature in this field.
Results:
There are government licensed viral gene therapy products currently in use for head and neck cancer, utilised in conjunction with established treatment modalities. The viruses target tumour-associated genes, with the first licensed virus replacing p53 gene function, which is frequently lost in tumourigenesis. Oncolytic viruses selectively destroy cancer cells through viral replication and can be armed with therapeutic transgenes.
Conclusion:
Despite considerable advances in this field over the last 40 years, further research is needed to improve the overall efficacy of the viruses and allow their widespread utilisation in the management of head and neck cancer.
Insights
Viral gene therapy offers a promising approach for head and neck cancer treatment. Current licensed viral therapies target tumor genes, with ongoing research focused on enhancing efficacy for broader clinical use.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Viral gene therapy represents a novel treatment strategy for head and neck cancers.
- This review synthesizes current literature on viral gene therapy applications in this field.
Purpose of the Study:
- To provide a comprehensive review of viral gene therapy for head and neck cancer.
- To highlight current advancements and future directions in the field.
Main Methods:
- Literature review of viral gene therapy for head and neck cancer.
- Analysis of existing government-licensed viral gene therapy products.
- Examination of viral mechanisms targeting tumor-associated genes.
Main Results:
- Licensed viral gene therapy products are available for head and neck cancer, used alongside conventional treatments.
- Viruses are engineered to target specific tumor genes, including the p53 tumor suppressor gene.
- Oncolytic viruses demonstrate selective cancer cell destruction via replication and can be modified to carry therapeutic genes.
Conclusions:
- Significant progress has been made in viral gene therapy for head and neck cancer over four decades.
- Further research is essential to optimize viral efficacy and facilitate wider adoption in patient management.
- Enhancing viral effectiveness is key to improving outcomes for head and neck cancer patients.
More Related Videos
05:45In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
Published on: January 9, 2020
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
Related Concept Videos
Gene Therapy
Gene Therapy
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
Microorganisms in Medicine and Therapeutics
Mechanisms of Retrovirus-induced Cancers